>

AbbVie Stock Analysis

<div class='circular--portrait' style='background:#CD0D74;color: white;font-size:3em;padding-top: 40px;;'>ABB</div>
ABBV -- USA Stock  

USD 89.18  3.96  4.25%

The current investor indifference towards the small price fluctuations of AbbVie could raise concerns from investors as the firm closed today at a share price of 88.11 on 11,011,281 in volume. The company directors and management did not add any value to AbbVie investors in January. However, most investors can still diversify their portfolios with AbbVie to hedge your portfolio against high-volatility market scenarios. The stock standard deviation of daily returns for 30 days (very short) investing horizon is currently 1.52. The below-average Stock volatility is a good sign for a longer term investment options and for buy-and-hold investors. The AbbVie financial analysis interface makes it easy to digest most current publicly released information about AbbVie as well as get updates on important government artifacts including earning estimates, SEC corporate filings and announcements. AbbVie stock analysis module also helps to analyze AbbVie price relationship with some important fundamental indicators such as market cap and management efficiency. Please continue to Trending Equities.
Equity
Refresh

AbbVie Stock Analysis Notes

About 77.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings To Growth (PEG) ratio of 2.64. AbbVie last dividend was issued on 2020-01-14. AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. AbbVie operates under Drug Manufacturers - General classification in USA and is traded on BATS Exchange. For more info on AbbVie Inc. Commo please contact Richard Gonzalez at 847 932-7900 or go to www.abbvie.com.

AbbVie Investment Alerts

Over 77.0% of the company shares are held by institutions such as insurance companies
On January 14, 2020 AbbVie paid $ 1.18 per share dividend to its current shareholders
Latest headline from newssmooth.com: Estimates could be Right AbbVie Inc., - NewsSmooth

AbbVie Upcoming and Recent Events

Upcoming Quarterly Earning ReportApril 23, 2020
Next Earnings ReportJuly 24, 2020
Next Fiscal Quarter EndMarch 31, 2020
Next Fiscal Year EndFebruary 5, 2021
Last Quarter Report DateDecember 31, 2019
Last Earning Anouncement DateMarch 31, 2019

AbbVie Earning Estimates

EPSEstimate Date
Quarterly Estimate2.23April 23, 2020
AbbVie normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  

AbbVie SEC Filings

Unclassified Corporate Event. Termination of a Material Definitive Agreement
Unclassified Corporate Event
Financial Statements and Exhibits. Results of Operations and Financial Condition
Unclassified Corporate Event
Financial Statements and Exhibits. Other Events
Financial Statements and Exhibits. Other Events
Financial Statements and Exhibits. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. Entry into a Material Definitive Agreement
Financial Statements and Exhibits. Other Events

AbbVie Thematic Classifications

Macroaxis Index IdeaMacroaxis Index
Macroaxis power theme of selected equities with solid fundamentals
Giant Impact IdeaGiant Impact
Public companies with mega capitalization

Institutional Investors

Security TypeSharesValue
Vanguard Group IncCommon Shares122.6 M10.9 B
Blackrock IncCommon Shares98.6 M8.7 B
Capital Research Global InvestorsCommon Shares86.6 M7.7 B
State Street CorpCommon Shares68.8 M6.1 B
Fmr LlcCommon Shares40.2 M3.6 B
Price T Rowe Associates IncCommon Shares28.1 M2.5 B
Geode Capital Management LlcCommon Shares24.4 M2.2 B

Market Capitalization

The company currently falls under 'Mega-Cap' category with current market capitalization of 137.35 B.

Institutional Stock Holders for AbbVie

Information
Ratio
Value
At Risk
NYSE(0.0478) (1.04) 
Nasdaq US Large Cap Value NTR I(0.0361) (1.81) 
NASDAQ US Large Mid Cap Index(0.0009) (1.82) 
Nasdaq US Smart Pharmaceuticals(0.11) (5.01) 
Nasdaq US Shareholder Yield Net(0.06) (2.36) 
Nasdaq US Shareholder Yield Ind(0.07) (2.37) 
NASDAQ N America Large Mid Cap(0.0002) (1.79) 
NASDAQ US Multi Asset Diversifi(0.06) (1.47) 
Nasdaq US Multi Asset Equity In(0.07) (2.33) 
Nasdaq Dorsey Wright Peoples Po(0.0044) (1.96) 
Nasdaq Singularity Net Total Re 0.0367 (1.66) 
Nasdaq Singularity Index 0.0197 (1.66) 
Dorsey Wright Momentum Plus Div(0.06) (2.67) 
NYSE ARCA PHARMACEUTICAL INDEX 0.0042 (1.61) 
Dow Jones U S Biotechnology In(0.0073) (2.22) 
Segall Bryant Hamill Workplac(0.08) (1.73) 
Victory Special Value Fd Cl Y(0.06) (2.07) 
Victory Special Value Fund Clas(0.07) (2.47) 
USAA Mutual Fds Tr Income Stock(0.13) (1.69) 
Transamerica Large Cap Value Cl(0.10) (1.58) 

Technical Drivers

As of the 25th of February AbbVie shows Risk Adjusted Performance of 0.0734 and Mean Deviation of 1.09. AbbVie technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm future prices. Put another way you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum or the prices will eventually revert. We found nineteen technical drivers for AbbVie, which can be compared to its rivals. Please confirm AbbVie Coefficient Of Variation as well as the relationship between Treynor Ratio and Semi Variance to decide if AbbVie is priced correctly providing market reflects its regular price of 89.18 per share. Given that AbbVie has Jensen Alpha of 0.0998, we suggest you validate AbbVie prevailing market performance to make sure the company can sustain itself at future point.

AbbVie Price Movement Analysis

The output start index for this execution was two with a total number of output elements of fifty-nine. The Mid-point Price over period is an average of AbbVie highest and lowest prices attained during the given period. View also all equity analysis or get more info about midpoint price over period overlap studies indicator.

AbbVie Insider Trading Activities

AbbVie Outstanding Bonds

MaturityCouponRating
00287YAG4 1.2%11/06/20151.2
A
00287YAJ8 1.75%11/06/20171.75
A
00287YAK5 2.0%11/06/20182.0
A
00287YAL3 2.9%11/06/20222.9
A
00287YAM1 4.4%11/06/20424.4
A
00287YAN9 1.8%05/14/20181.8
A
00287YAP4 3.2%11/06/20223.2
A
00287YAQ2 3.6%05/14/20253.6
A
00287YAR0 4.5%05/14/20354.5
A
00287YAS8 4.7%05/14/20454.7
A
00287YAT6 2.5%05/14/20202.5
A

AbbVie Predictive Indicators

AbbVie Forecast Models

Recommendations

AbbVie Analyst Recommendations

Target PriceAdvice# of Analysts
93.33Buy9Odds
AbbVie current and past analyst recommendations published by number of research institutions as well as average analyst consensus
AbbVie Analyst Advice  

Vital Value Indicators

AbbVie Basic Pricing Drivers

Fifty Two Week Low62.66
Trailing Annual Dividend Rate4.39
Revenue Growth4.80%
Payout Ratio81.06%
Average Daily Volume Last 10 Day10.4M
Shares Short Prior Month71.95M
Average Daily Volume In Three Month8.42M
Shares Percent Shares Out5.05%
Gross Margins77.71%
Forward Price Earnings8.96
Short Percent Of Float5.73%
Float Shares1.48B
Fifty Two Week High97.86
Fifty Day Average88.63
Enterprise Value To Ebitda10.55
Two Hundred Day Average80.00
Trailing Annual Dividend Yield4.66%
Enterprise Value To Revenue5.03
Please continue to Trending Equities. Please also try Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Company logos by clearbit